CDK4 and non-small cell lung carcinoma: Potential targeted therapies, such as anti-PD-1 antibodies and CDK4/6 inhibitors, have been reported for treating SMARCA4-deficient non-small cell lung cancer (SMARCA4-deficient NSCLC) [1, 6].